Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Allogene Therapeutics Inc’s stock clocked out at $1.27, up 3.25% from its previous closing price of $1.23. In other words, the price has increased by $3.25 from its previous closing price. On the day, 3.78 million shares were traded. ALLO stock price reached its highest trading level at $1.33 during the session, while it also had its lowest trading level at $1.2.
Ratios:
To gain a deeper understanding of ALLO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.92 and its Current Ratio is at 8.92. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.23.
Citizens JMP Upgraded its Mkt Perform to Mkt Outperform on March 14, 2025, while the target price for the stock was maintained at $5.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 10 ’25 when MESSEMER DEBORAH M. sold 36,885 shares for $1.42 per share. The transaction valued at 52,377 led to the insider holds 107,431 shares of the business.
MESSEMER DEBORAH M. bought 36,885 shares of ALLO for $52,391 on Jun 10 ’25. On Apr 21 ’25, another insider, Yoshiyama Annie, who serves as the SVP, Finance of the company, sold 9,601 shares for $1.41 each. As a result, the insider received 13,537 and left with 130,663 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALLO now has a Market Capitalization of 281788896 and an Enterprise Value of 95665904.
Stock Price History:
The Beta on a monthly basis for ALLO is 0.41, which has changed by -0.5313653 over the last 52 weeks, in comparison to a change of 0.1443547 over the same period for the S&P500. Over the past 52 weeks, ALLO has reached a high of $3.78, while it has fallen to a 52-week low of $0.86. The 50-Day Moving Average of the stock is 8.44%, while the 200-Day Moving Average is calculated to be -13.76%.
Shares Statistics:
It appears that ALLO traded 3.94M shares on average per day over the past three months and 3233320 shares per day over the past ten days. A total of 220.13M shares are outstanding, with a floating share count of 153.71M. Insiders hold about 30.72% of the company’s shares, while institutions hold 60.65% stake in the company. Shares short for ALLO as of 1759190400 were 19201999 with a Short Ratio of 4.88, compared to 1756425600 on 19943094. Therefore, it implies a Short% of Shares Outstanding of 19201999 and a Short% of Float of 10.4499996.
Earnings Estimates
. The current rating of Allogene Therapeutics Inc (ALLO) reflects the combined expertise of 7.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.22, with high estimates of -$0.19 and low estimates of -$0.24.
Analysts are recommending an EPS of between -$0.96 and -$1.2 for the fiscal current year, implying an average EPS of -$1.03. EPS for the following year is -$0.98, with 10.0 analysts recommending between -$0.5 and -$1.47.
